SEC Form 4 · accession 0000899243-19-005884

REPLIGEN CORP · RGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Feb 28, 2019

Accepted (ET)

Mar 4, 2019 · 6:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000730272

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 28, 2019	A	22,681	$0.00	A	250,132	D
Common Stock^F3	Feb 28, 2019	S	7,475	$59.01	D	242,657	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$59.52	Feb 28, 2019	A	21,651	A	—	Feb 28, 2029	Common Stock	21,651	21,651	D

F1Mr. Hunt was awarded 22,681 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2Sale of 7,475 shares in the open market to cover tax liability resulting from the release of restricted stock units.
F3$59.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.75 to $59.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022.